Advertisement

Special Diagnostics

  • Regina Kunzmann
  • Michael Luebbert
  • Hendrik Veelken
  • Jürgen Scheele
  • Uwe Martens
  • Rupert Engelhardt
  • Sebastian Fetscher
  • Florian Otto
  • D. Behringer
  • Eva Jüttner
  • Jan Burger
  • Meike Burger
  • Carsten Grüllich
  • Leonora Houet
  • Jürgen Finke
Chapter

Keywords

Acute Myeloid Leukemia Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Acute Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bordeleau L, Berinstein NL. Molecular diagnostics in follicular non-Hodgkin’s lymphoma. Semin Oncol 2000;27(6 Suppl 12):42–52PubMedGoogle Scholar
  2. 2.
    Burmeister T, Thiel E. Molecular genetics in acute and chronic leukemias. J Cancer Res Clin Oncol 2001;127:80–90PubMedCrossRefGoogle Scholar
  3. 3.
    Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322–33PubMedGoogle Scholar
  4. 4.
    Harrison CJ. The management of patients with leukaemia: the role of cytogenetics in this molecular era. Br J Hematol 2000;108:19–30CrossRefGoogle Scholar
  5. 5.
    Huret JL, Dessen P, LeMinor S et al. The “Atlas of Genetics and Cytogenetics in Oncology and Haematology” on the internet and a review on infant leukemias. Cancer Genet Cytogenet 2000;120:155–9PubMedCrossRefGoogle Scholar
  6. 6.
    Kristensen TD, Wesenberg F et al. High-resolution comparative genomic hybridisation yields a high detection rate of chromosomal aberrations in childhood acute lymphoblastic leukaemia. Eur J Haematol 2003;70:363–72PubMedCrossRefGoogle Scholar
  7. 7.
    Mrozek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol 2000;72:261–71PubMedGoogle Scholar
  8. 1.
    http://www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html NIH gene databaseGoogle Scholar
  9. 2.
    http://www.gdb.org/ Human Genome DatabaseGoogle Scholar
  10. 3.
    http://atlasgeneticsoncology.org/ Atlas of Genetics and CytogeneticsGoogle Scholar
  11. 4.
    http://www.slh.wisc.edu/cytogenetics/index.php Cancer CytogeneticsGoogle Scholar
  12. 5.
    http://www.biologia.uniba.it/rmc/ Molecular Cytogenetics ResourcesGoogle Scholar
  13. 6.
    http://www.genenames.org/ Human Gene NomenclatureGoogle Scholar
  14. 1.
    Cassinat B, Zassadowski F, Balitrand N et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT–PCR. Leukemia 2000;14:324–8PubMedCrossRefGoogle Scholar
  15. 2.
    Krauter J, Pascheberg U, Heinze B et al. Detection of karyotypic aberrations in acute myeloblastic leukemia (AML): a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol 1998;103:72–8PubMedCrossRefGoogle Scholar
  16. 3.
    Perez EA, Pusztai L, Van de Vijver M. Improving patient care through molecular diagnostics. Semin Oncol 2004;31(5 Suppl 10):14–20PubMedCrossRefGoogle Scholar
  17. 4.
    Schoch C, Kohlmann A et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expressions profiles. Proc Natl Acad Sci U S A 2002;99:10008–13PubMedCrossRefGoogle Scholar
  18. 5.
    Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003;348:1777–85PubMedCrossRefGoogle Scholar
  19. 6.
    Varella-Garcia M. Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy. Oncologist 2003;8:45–58PubMedCrossRefGoogle Scholar
  20. 1.
    http://jmd.amjpathol.org Journal of Molecular DiagnosticsGoogle Scholar
  21. 2.
    http://www.acmg.net/ American College of Medical GeneticsGoogle Scholar
  22. 3.
    http://www.abgc.net/ American Board of Genetic CounselingGoogle Scholar
  23. 4.
    http://www.eshg.org European Society of Human GeneticsGoogle Scholar
  24. 5.
    http://www.eurogene.org/index.php European Genetics FoundationGoogle Scholar
  25. 6.
    http://genetics.faseb.org/genetics/acmg/stds/g.htm ACMG Standards and GuidelinesGoogle Scholar
  26. 1.
    Baak JPA, Path FRC, Hermsen MAJA et al. Genomics and proteomics in cancer. Eur J Cancer 2003;39:1199–215PubMedCrossRefGoogle Scholar
  27. 2.
    Bullinger L, Döhner K, Bair E et al. Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605–16PubMedCrossRefGoogle Scholar
  28. 3.
    Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood 2004;104:923–32PubMedCrossRefGoogle Scholar
  29. 4.
    Hubank M. Gene expression profiling and its application in studies of haematological malignancy. Br J Haematol 2004;124:577–94PubMedCrossRefGoogle Scholar
  30. 5.
    Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354:2463–72PubMedCrossRefGoogle Scholar
  31. 6.
    Ramaswamy S, Ross KN, Lander ES et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49–54PubMedCrossRefGoogle Scholar
  32. 7.
    Rosenwald AR, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–47PubMedCrossRefGoogle Scholar
  33. 8.
    Van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009PubMedCrossRefGoogle Scholar
  34. 1.
    http://dc.nci.nih.gov/dc/ NCI, Molecular Classification of CancerGoogle Scholar
  35. 2.
    http://genome-www5.stanford.edu/ Stanford Microarray DatabaseGoogle Scholar
  36. 3.
    http://www.ebi.ac.uk/arrayexpress/ EBI Transciptional DatabaseGoogle Scholar
  37. 4.
    http://www.genome.ad.jp/kegg/kegg2.html KEGG, Biochemical PathwaysGoogle Scholar
  38. 5.
    http://genmapp.org GenMapp, Biochemical PathwaysGoogle Scholar
  39. 6.
    http://affymetrix.com Affymetrix MicroarraysGoogle Scholar
  40. 1.
    Brawer MK. Prostate-specific antigen: current status. CA Cancer J Clin 1999;49:264–81PubMedCrossRefGoogle Scholar
  41. 2.
    Gion M, Mione R, Barioli P et al. Dynamic use of tumor markers: rationale, clinical applications and pitfalls. Anticancer Res 1996;16:2279–84PubMedGoogle Scholar
  42. 3.
    Locker GY, Hamilton S, Harris J et al. ASCO 2006 Update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313–27PubMedCrossRefGoogle Scholar
  43. 4.
    Rapkiewicz AV, Espina V, Petricoin EF et al. Biomarkers of ovarian tumours. Eur J Cancer 2004;40:2604–12PubMedCrossRefGoogle Scholar
  44. 5.
    Scher HI, Eisenberger M, D’Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen. Recommendations from the PSA Working Group. J Clin Oncol 2004;22:537–56PubMedCrossRefGoogle Scholar
  45. 6.
    Sölétormos G, Nielsen D, Schioler V et al. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 2004;40:481–6PubMedCrossRefGoogle Scholar
  46. 1.
    http://www.asco.org ASCO Tumor Marker GuidelinesGoogle Scholar
  47. 2.
    http://oncolink.upenn.edu/ Oncolink, Tumor Marker Fact SheetGoogle Scholar
  48. 3.
    http://cancernet.nci.nih.org/ Tumor Marker Fact SheetsGoogle Scholar
  49. 1.
    Bene M, Castoldi G, Knapp W et al. Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783–6PubMedGoogle Scholar
  50. 2.
    Bennett J, Catovskz D, Daniel M et al. Proposed revised criteria for the classification of acute myeloid leukemias. Ann Intern Med 1985;103:626–9Google Scholar
  51. 3.
    Cheson B, Cassileth P, Head D et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813–9PubMedGoogle Scholar
  52. 4.
    Gratama JW, Sutherland DR, Keeney M. Flow cytometric enumeration and immunophenotyping of hematopoietic stem and progenitor cells. Semin Hematol 2001;38:139–47PubMedCrossRefGoogle Scholar
  53. 5.
    Harris NL, Jaffe E, Stein H et al. A Revised European-American Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–92PubMedGoogle Scholar
  54. 6.
    Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–49PubMedGoogle Scholar
  55. 7.
    Mason D et al (eds). Leucocyte Typing VII. Oxford University Press, 2001Google Scholar
  56. 8.
    Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001;38:111–23PubMedCrossRefGoogle Scholar
  57. 9.
    Vardiman J, Harris NL, Brunning RD; the World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302PubMedCrossRefGoogle Scholar
  58. 10.
    Zola H, Swart B, Nicholson I et al. CD molecules 2005: Human cell differentiation molecules. Blood 2005;106:3123–3126PubMedCrossRefGoogle Scholar
  59. 1.
    http://image.bloodline.net/ Picture Atlas, BloodlineGoogle Scholar
  60. 2.
    http://www.hlda8.org HLDA WorkshopGoogle Scholar
  61. 3.
    http://mpr.nci.nih.quv/prow Flow Cytometry DatabaseGoogle Scholar
  62. 1.
    Fisch P, Moris A, Rammensee HG et al. Inhibitory MHC class I receptors on gammadelta T cells in tumour immunity and autoimmunity. Immunol Today 2000;21:187–191PubMedCrossRefGoogle Scholar
  63. 2.
    Godsell DS. The molecular perspective: MHC. Oncologist 2005;10:80–1CrossRefGoogle Scholar
  64. 3.
    Klein J, Sato A. The HLA System. N Engl J Med 2000;243:702–9, 782–6Google Scholar
  65. 4.
    Marsh SG, Bodmer JG, Albert ED et al. Nomenclature for factors of the HLA system, 2000. Tissue Antigens 2001;57:236–83PubMedCrossRefGoogle Scholar
  66. 1.
    http://www.ashi-hla.org/ American Society for Histocompatibility and ImmunogeneticsGoogle Scholar
  67. 2.
    http://www.ihwg.org/ International Histocompatibility Working GroupGoogle Scholar
  68. 3.
    http://www.worldmarrow.org WMDA, World Marrow Donor AssociationGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Regina Kunzmann
    • 1
  • Michael Luebbert
    • 1
  • Hendrik Veelken
    • 1
  • Jürgen Scheele
    • 1
  • Uwe Martens
    • 2
  • Rupert Engelhardt
    • 3
  • Sebastian Fetscher
    • 4
  • Florian Otto
    • 1
  • D. Behringer
    • 5
  • Eva Jüttner
    • 6
  • Jan Burger
    • 7
  • Meike Burger
    • 1
  • Carsten Grüllich
    • 1
  • Leonora Houet
    • 1
  • Jürgen Finke
    • 8
  1. 1.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  2. 2.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  3. 3.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  4. 4.Klinik für Hämatologie/Onkologie, Städt. Krankenhaus SüdSana Kliniken LübeckLübeckGermany
  5. 5.Hematology, OncologyAugusta-Kranken-AnstaltBochumGermany
  6. 6.Department of PathologyUniversity Medical CenterFreiburgGermany
  7. 7.MD AndersonHoustonGermany
  8. 8.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany

Personalised recommendations